Business ❯ Corporate Strategy ❯ Regulatory Compliance ❯ FDA Interactions

Data Submission

Capricor Seeks New FDA Path for Duchenne Drug After 9–3 Advisory Vote

The company will submit an amended BLA focused on upper‑limb function and the FDA has agreed to review the data, a move that could push back the Aug. 22 decision date.